Newbridge Financial Services Group Inc. purchased a new stake in Verve Therapeutics, Inc. (NASDAQ:VERV – Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 2,182 shares of the company’s stock, valued at approximately $30,000.
Several other institutional investors have also made changes to their positions in the stock. ARK Investment Management LLC boosted its stake in shares of Verve Therapeutics by 35.1% in the fourth quarter. ARK Investment Management LLC now owns 7,025,116 shares of the company’s stock valued at $97,930,000 after buying an additional 1,824,549 shares during the period. FMR LLC boosted its stake in shares of Verve Therapeutics by 8.8% in the third quarter. FMR LLC now owns 6,577,562 shares of the company’s stock valued at $87,218,000 after buying an additional 531,182 shares during the period. Vanguard Group Inc. boosted its stake in shares of Verve Therapeutics by 18.1% in the third quarter. Vanguard Group Inc. now owns 4,832,968 shares of the company’s stock valued at $64,085,000 after buying an additional 741,753 shares during the period. Federated Hermes Inc. boosted its stake in shares of Verve Therapeutics by 57.2% in the fourth quarter. Federated Hermes Inc. now owns 3,980,372 shares of the company’s stock valued at $55,486,000 after buying an additional 1,448,003 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. boosted its stake in shares of Verve Therapeutics by 11.7% in the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,397,604 shares of the company’s stock valued at $33,423,000 after buying an additional 250,361 shares during the period. 97.11% of the stock is currently owned by institutional investors.
Verve Therapeutics Price Performance
Shares of Verve Therapeutics stock opened at $5.10 on Wednesday. Verve Therapeutics, Inc. has a twelve month low of $4.90 and a twelve month high of $21.04. The company’s fifty day moving average is $6.10 and its 200 day moving average is $10.60.
Analysts Set New Price Targets
Several research analysts have commented on the stock. Royal Bank of Canada restated an “outperform” rating and set a $35.00 price objective on shares of Verve Therapeutics in a research report on Wednesday, February 28th. Stifel Nicolaus lowered their price target on shares of Verve Therapeutics from $56.00 to $40.00 and set a “buy” rating for the company in a report on Wednesday, April 3rd. Finally, HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Verve Therapeutics in a report on Thursday, May 9th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $33.00.
Read Our Latest Stock Report on VERV
Insider Buying and Selling
In other news, insider Andrew D. Ashe purchased 76,000 shares of the business’s stock in a transaction on Tuesday, May 14th. The shares were acquired at an average price of $6.26 per share, with a total value of $475,760.00. Following the completion of the transaction, the insider now owns 342,509 shares of the company’s stock, valued at approximately $2,144,106.34. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. 19.30% of the stock is currently owned by insiders.
Verve Therapeutics Company Profile
Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.
Featured Stories
- Five stocks we like better than Verve Therapeutics
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Occidental Stock: Buffett’s 9-Day Buying Spree Lifts Stake to 29%
- How to Use the MarketBeat Stock Screener
- 3M Stock: Invest Now for Unmatched Quality and Growth Potential
- What is the Shanghai Stock Exchange Composite Index?
- Super Micro AI Stock: Should You Invest After a 275% Increase?
Want to see what other hedge funds are holding VERV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Verve Therapeutics, Inc. (NASDAQ:VERV – Free Report).
Receive News & Ratings for Verve Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verve Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.